Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +45

Gilead Sciences Stock (GILD) Opinions on Recent Congressional Insider Activity - Quiver Quantitative

AI-generated analysis

πŸ“‰ Gilead insiders sold approximately $54 million in shares over the last six months with zero purchases recorded.

πŸ‘” Three members of Congress purchased roughly $45,000 worth of GILD stock recently, contrasting with executive sales.

πŸ’° Q1 2026 revenue reached $7 billion, marking a 4.39% increase compared to the same period last year.

🏦 FMR LLC added $871.5 million in shares, while BlackRock and Barclays collectively reduced positions by over $1.1 billion.

πŸ“ˆ Needham issued a 'Buy' rating on GILD, contributing to a positive analyst sentiment environment.

🎯 Analyst price targets for the stock range from $122 to $180, with a median target set at $165.

πŸ’Š The company is advancing its pipeline via licensing deals for STAT6 inhibitor programs targeting inflammation.

πŸ“… Data readouts for new oral therapies are anticipated around mid-2027 as part of competitive positioning.

Bullish Signals
  • Gilead Sciences reported Q1 2026 revenues of $7 billion, a solid 4.39% year-over-year increase.
  • Major institutional investor FMR LLC added 6.3 million shares worth approximately $871.5 million to its portfolio in Q1 2026.
  • Wall Street analysts show bullish sentiment with Needham issuing a 'Buy' rating and twelve analysts setting price targets between $122 and $180.
  • The company is strategically expanding its pipeline through licensing deals for STAT6 inhibitor programs to advance oral therapies in the inflammation space.
Risk Factors
  • Gilead insiders, including the CEO and CFO, executed significant sales totaling approximately $54 million over the last six months with no corresponding purchases.
  • Major institutional holders like BlackRock and Barclays reduced their positions by over $1.1 billion combined in Q1 2026, indicating some profit-taking or rotation.
  • Several analysts set price targets below current market expectations, such as RBC Capital at $122 and Citigroup at $155, suggesting potential downside risk relative to higher targets like Jefferies' $180.
Full Analysis
Gilead Sciences (GILD) recently saw a mix of insider and congressional trading activity. While the company's CEO, Chairman, CFO, and other executives sold a total of approximately $54 million in shares over the last six months with no purchases, several members of Congress made small purchases totaling around $45,000. This divergence has sparked social media discussion regarding potential signals for the biotech sector. Financially, Gilead reported Q1 2026 revenues of $7 billion, representing a 4.39% increase year-over-year. Institutional investor sentiment remains mixed, with major firms like FMR LLC adding nearly $872 million to their positions while BlackRock and Barclays reduced holdings by over $576 million and $528 million respectively in Q1 2026. Wall Street analysts maintain a generally positive outlook on the stock. Needham issued a 'Buy' rating, and twelve analysts have set price targets ranging from $122 to $180, with a median target of $165. The company is also advancing its pipeline through recent licensing deals for STAT6 inhibitor programs aimed at oral therapies for inflammation, with data readouts expected in mid-2027.